Biocartis
Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 15 % | 22 % | 34 % | 15 % | 12 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (200 %) | (165 %) | (150 %) | (126 %) | (99 %) | (108 %) | (76 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (183 %) | (171 %) | (171 %) | (146 %) | (148 %) | (114 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 106 % | 106 % | 91 % | 67 % |
Source: Company filings or news article
Related Content
Biocartis is a pioneering molecular diagnostics company dedicated to transforming molecular testing through its unique IdyllaTM platform. The company provides advanced diagnostic solutions designed to improve clinical practice for patients, clinicians, payers, and the broader healthcare industry. Biocartis operates in the molecular diagnostics market, focusing on oncology and infectious diseases. Its primary clients include hospitals, laboratories, and healthcare providers who require rapid and accurate diagnostic results. The business model revolves around the sale of diagnostic instruments and consumables, generating revenue through the continuous use of its proprietary platform and assays. Biocartis makes money by selling its IdyllaTM platform and associated diagnostic tests, which offer quick and reliable results, thereby enhancing patient care and operational efficiency in clinical settings.
Keywords: molecular diagnostics, Idylla platform, oncology, infectious diseases, clinical practice, healthcare providers, rapid testing, diagnostic solutions, proprietary technology, patient care.
